Joshua Woolley

2.4k total citations · 1 hit paper
22 papers, 609 citations indexed

About

Joshua Woolley is a scholar working on Clinical Psychology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Joshua Woolley has authored 22 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Clinical Psychology, 14 papers in Organic Chemistry and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Joshua Woolley's work include Psychedelics and Drug Studies (15 papers), Chemical synthesis and alkaloids (14 papers) and Neurotransmitter Receptor Influence on Behavior (6 papers). Joshua Woolley is often cited by papers focused on Psychedelics and Drug Studies (15 papers), Chemical synthesis and alkaloids (14 papers) and Neurotransmitter Receptor Influence on Behavior (6 papers). Joshua Woolley collaborates with scholars based in United States, Canada and United Kingdom. Joshua Woolley's co-authors include Christopher S. Stauffer, B. Anderson, Jacob S. Aday, Ellen Bradley, Raymond C. Rosen, Boris D. Heifets, Steven D. Pratscher, Alicia Danforth, Jennifer Mitchell and Matthew Tyler Boden and has published in prestigious journals such as Biological Psychiatry, Neuroscience & Biobehavioral Reviews and Neuropsychopharmacology.

In The Last Decade

Joshua Woolley

20 papers receiving 598 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials

2022 133 citations Jacob S. Aday, Boris D. Heifets et al. Psychopharmacology profile →

Peers

Countries citing papers authored by Joshua Woolley

Since Specialization

Citations

This map shows the geographic impact of Joshua Woolley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Woolley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Woolley more than expected).

Fields of papers citing papers by Joshua Woolley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Woolley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Woolley. The network helps show where Joshua Woolley may publish in the future.

Co-authorship network of co-authors of Joshua Woolley

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Woolley. A scholar is included among the top collaborators of Joshua Woolley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Woolley. Joshua Woolley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial 2025 ·Neuropsychopharmacology ·Ellen Bradley, (unknown), (unknown), Balázs Szigeti, (unknown), Jill L. Ostrem, Caroline M. Tanner, Meredith Bock, Katiah Llerena, Patrick R. Finley, Aoife O’Donovan, (unknown), (unknown), (unknown), Andrew Penn, (unknown), Raymond C. Rosen, Joshua Woolley	2
2	The allostatic triage model of psychopathology (ATP Model): How reallocation of brain energetic resources under stress elicits psychiatric symptoms 2025 ·Neuroscience & Biobehavioral Reviews ·(unknown), S. Parker Singleton, (unknown), (unknown), Anne Mette Skovgaard, Joseph Francis, Thomas C. Neylan, Ellen Bradley, Joshua Woolley, Martin Picard, Aoife O’Donovan	1
3	A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy? 2024 ·PubMed ·Amanda E. Downey, Ellen Bradley, (unknown), Aoife O’Donovan, Andrew D. Krystal, Joshua Woolley	0
4	Psychedelic-assisted psychotherapy: where is the psychotherapy research? 2024 ·Psychopharmacology ·Jacob S. Aday, (unknown), (unknown), Aoife O’Donovan, Ellen Bradley, Raymond C. Rosen, Joshua Woolley	15
5	Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms 2024 ·Psychopharmacology ·(unknown), Ellen Bradley, (unknown), Gabrielle Agin-Liebes, (unknown), (unknown), (unknown), (unknown), Emma Morton, Erin E. Michalak, Aoife O’Donovan, Joshua Woolley	4
6	SUSTAINABLE INNOVATION THROUGH DATADRIVEN DESIGN USING LIFECYCLE ANALYSIS (LCA) METHODOLOGY 2023 ·(unknown), Joshua Woolley, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
7	“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy 2023 ·International Journal of Eating Disorders ·Amanda E. Downey, (unknown), (unknown), Joshua Woolley, Marissa Raymond‐Flesch	4
8	Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice 2023 ·PubMed ·Jacob S. Aday, (unknown), (unknown), (unknown), (unknown), (unknown), Ellen Bradley, (unknown), Joshua Woolley	21
9	Emerging Challenges for Psychedelic Therapy 2023 ·JAMA Psychiatry ·Jacob S. Aday, Robin Carhart‐Harris, Joshua Woolley	30
10	Posttraumatic stress disorder symptoms associated with protective and risky behaviors for coronavirus disease 2019. 2022 ·Health Psychology ·Kristen Nishimi, Brian Borsari, Brian P. Marx, (unknown), Eleanor Woodward, Raymond C. Rosen, Beth E. Cohen, (unknown), (unknown), Joshua Woolley, Thomas C. Neylan, Aoife O’Donovan	9
11	Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials breakdown → 2022 ·Psychopharmacology ·Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher, Ellen Bradley, Raymond C. Rosen, Joshua Woolley	133
12	Psilocybin for Trauma-Related Disorders 2022 ·Current topics in behavioral neurosciences ·Amanda Khan, Ellen Bradley, Aoife O’Donovan, Joshua Woolley	27
13	Clusters of COVID-19 protective and risky behaviors and their associations with pandemic, socio-demographic, and mental health factors in the United States 2021 ·Preventive Medicine Reports ·Kristen Nishimi, Brian Borsari, Brian P. Marx, Raymond C. Rosen, Beth E. Cohen, Eleanor Woodward, (unknown), (unknown), (unknown), Joshua Woolley, Thomas C. Neylan, Aoife O’Donovan	13
14	Evaluating the risk of psilocybin for the treatment of bipolar depression: A review of the research literature and published case studies 2021 ·Journal of Affective Disorders Reports ·David E. Gard, (unknown), Ellen Bradley, Andrew Penn, (unknown), Lauren S. Riley, (unknown), (unknown), Erin E. Michalak, Joshua Woolley	24
15	Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience 2020 ·ACS Pharmacology & Translational Science ·Christopher S. Stauffer, B. Anderson, Kile Ortigo, Joshua Woolley	46
16	Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study 2020 ·EClinicalMedicine ·B. Anderson, Alicia Danforth, (unknown), Christopher S. Stauffer, Eve Ekman, Gabrielle Agin-Liebes, (unknown), Matthew Tyler Boden, (unknown), Jennifer Mitchell, Joshua Woolley	177
17	Social integration and inflammation in individuals with and without posttraumatic stress disorder 2020 ·Brain Behavior and Immunity ·(unknown), (unknown), Thomas C. Neylan, Joshua Woolley, Aoife O’Donovan, Beth E. Cohen	6
18	Psychedelic-Assisted Group Therapy: A Systematic Review 2019 ·Journal of Psychoactive Drugs ·(unknown), B. Anderson, (unknown), (unknown), Christopher S. Stauffer, Joshua Woolley	72
19	T137. Psilocybin-Assisted Group Therapy for Demoralization in Long-Term AIDS Survivors 2019 ·Biological Psychiatry ·B. Anderson, Alicia Danforth, Robert B. Daroff, Christopher S. Stauffer, James Dilley, Jennifer Mitchell, Joshua Woolley	4
20	American Alcohol Photo Stimuli (AAPS): A standardized set of alcohol and matched non-alcohol images 2016 ·The American Journal of Drug and Alcohol Abuse ·Christopher S. Stauffer, (unknown), Joshua Woolley	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact